ACB — Aurora Cannabis Inc.

ACB Q1 2027 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $67.6 million, with a 17% increase in international medical cannabis revenue to $43 million, primarily driven by growth in Germany.
• Adjusted Gross Margin: 58%, at the high end of the annual guidance range.
• Adjusted EBITDA: $3.4 million, down from $10.8 million year-over-year.
• Adjusted Net Income: $3.8 million, compared to $6.6 million last year.
• Cash Position: Nearly $150 million in cash and equivalents, with no debt.
• Free Cash Flow: Outflow of $5.8 million, compared to an inflow of $6.8 million in the prior year.

2. Strategic Updates and Business Highlights

• Focus on medical cannabis has solidified Aurora's position in key markets, with significant market share in Canada, Germany, Poland, and Australia.
• Acquisition of Safari Flower Company enhances manufacturing capacity and supports international expansion.
• Continued investment in genetics and operational efficiencies has led to reduced production costs and improved product quality.
• Strong performance in international markets, with 64% of total revenue generated outside Canada, up from 50% last year.
• Expansion plans for the Leuna facility in Germany are nearing completion, expected to double annual flower output.

3. Forward Guidance and Outlook

• Anticipated revenue and adjusted EBITDA for Q2 2027 are expected to be substantially higher than Q1.
• Fiscal 2027 is viewed as a transition year, with growth in international markets expected to offset challenges in the Canadian medical market.
• Continued investment in international business and strategic initiatives to drive growth in profitable markets.

4. Bad News, Challenges, or Points of Concern

• Canadian medical cannabis revenue has been impacted by a 30% reduction in reimbursement rates, leading to a decline in adjusted gross profit.
• Adjusted EBITDA and net income have decreased year-over-year, reflecting lower gross profit before fair value adjustments.
• Pricing pressures in the German market, particularly in the value segment, could impact margins, although premium and core segments remain stable.
• Regulatory uncertainties in the U.S. and potential competitive pressures from U.S. growers entering international markets.

5. Notable Q&A Insights

• Management expressed confidence in sequential revenue growth driven by strong performance in Germany, Poland, Australia, and New Zealand.
• The integration of Safari Flower Company is progressing well, with early contributions noted in Q1.
• Concerns about pricing pressure in Germany were acknowledged, but management believes their established position and GMP standards provide a competitive advantage.
• Management indicated that while they are monitoring the U.S. regulatory landscape, they see potential for partnerships and opportunities stemming from changes in U.S. cannabis regulations.

Overall, while Aurora faces challenges in the Canadian market due to reimbursement changes, its strong international presence and strategic investments position it well for future growth.